000			02338 a2200637 4500
005			20250514015316.0
264		0	_c20020520
008			200205s 0 0 eng d
022			_a0927-3042
024	7		_a10.1007/978-1-4615-1463-3_12 _2doi
040			_aNLM _beng _cNLM
100	1		_aGojo, I
245	0	0	_aThe impact of biology on the treatment of secondary AML. _h[electronic resource]
260			_bCancer treatment and research _c2001
300			_a231-55 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAcute Disease
650	0	4	_aAngiogenesis Inhibitors _xtherapeutic use
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aAntineoplastic Agents, Alkylating _xadverse effects
650	0	4	_aChromosome Deletion
650	0	4	_aChromosomes, Human, Pair 11 _xgenetics
650	0	4	_aChromosomes, Human, Pair 7 _xgenetics
650	0	4	_aDNA Methylation
650	0	4	_aDNA-Binding Proteins _xgenetics
650	0	4	_aEnzyme Inhibitors _xadverse effects
650	0	4	_aForecasting
650	0	4	_aGenes, Tumor Suppressor
650	0	4	_aHematopoietic Stem Cells _xdrug effects
650	0	4	_aHistone Deacetylase Inhibitors
650	0	4	_aHistone-Lysine N-Methyltransferase
650	0	4	_aHumans
650	0	4	_aLeukemia, Experimental _xetiology
650	0	4	_aLeukemia, Myeloid _xchemically induced
650	0	4	_aLeukemia, Radiation-Induced _xpathology
650	0	4	_aMice
650	0	4	_aMice, Inbred NOD
650	0	4	_aMice, SCID
650	0	4	_aMyeloid-Lymphoid Leukemia Protein
650	0	4	_aNeoplasm Proteins _xantagonists & inhibitors
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aNeoplasms, Second Primary _xchemically induced
650	0	4	_aNeoplastic Stem Cells _xdrug effects
650	0	4	_aNeovascularization, Pathologic _xdrug therapy
650	0	4	_aOncogene Proteins, Fusion _xgenetics
650	0	4	_aProto-Oncogenes
650	0	4	_aStromal Cells _xpathology
650	0	4	_aTopoisomerase II Inhibitors
650	0	4	_aTranscription Factors
650	0	4	_aTranslocation, Genetic
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aKarp, J E
773	0		_tCancer treatment and research _gvol. 108 _gp. 231-55
856	4	0	_uhttps://doi.org/10.1007/978-1-4615-1463-3_12 _zAvailable from publisher's website
999			_c11617835 _d11617835